Drugmakers race to find a place in the next wave of obesity drugs

Drugmakers are expanding the obesity pipeline beyond weekly GLP-1 injections, with oral pills, monthly shots, and non-GLP-1 treatments such as amylin all moving forward. Lilly highlighted retatrutide Phase 3 data showing up to 28% average weight loss at the highest dose, while Novo said Wegovy pill prescriptions topped 3 million within five months of launch. The article suggests a larger, more competitive obesity market ahead, though pricing pressure and reimbursement remain key risks.

Analysis

The near-term winner is still Lilly, but the more important implication is that the category is fragmenting from a single-shot, weekly-injection franchise into a platform war across route, duration, and tolerability. That shifts the moat away from pure efficacy and toward distribution, payer access, and persistence: the drug that is easiest to stay on will likely capture disproportionate refill economics even if it is not the most potent. Novo’s oral push is strategically important because it broadens the pool of treatable patients, but it also risks cannibalizing its own injectable mix faster than the market can expand, especially if insurers continue to tighten step therapy and reimbursement.

The second-order trade is on manufacturing and service intensity. Monthly or quarterly products reduce injection burden but do not eliminate the need for biologics-grade capacity, fill-finish, and patient support infrastructure; companies with flexible supply chains and strong specialty pharmacy relationships should gain share as adherence becomes the differentiator. This is also why the competitive threat from smaller entrants is more real than the market usually prices: if they can deliver meaningfully better tolerability, they do not need to beat Lilly on weight-loss absolute; they only need to win the persistence curve, where even a few percentage points of higher six- and twelve-month retention can matter enormously.

The biggest risk to the bull case is not efficacy failure, but payer compression. As access broadens into Medicare and employer plans, the category may get normalized into chronic disease management with much lower net prices than current street expectations, which would cap the upside for everyone except the most scaled players. In that environment, the market could overestimate the long-run value of late-2020s oral entrants while underestimating how much of the economics accrue to incumbents that can fund rebates, evidence generation, and combination pipelines.

Key Decisions for Investors

• Long NVO vs short basket of small-cap obesity entrants for 3-6 months: the market is likely overpaying for distant 2029 oral optionality while underestimating Novo's ability to monetize access expansion sooner; use a 1.5-2.0x downside-to-upside ratio with strict stop if payer commentary deteriorates.
• Buy AMGN on 6-12 month horizon into monthly/quarterly-dosing optionality: the stock offers underappreciated convenience leverage if adherence data translate, and the catalyst path is clinical rather than commercial; target a 20-30% rerate if durability signals hold.
• Pair long PFE / short compounding-exposed obesity beneficiaries for 1-3 months only if monthly dosing data keep improving: Pfizer's acquisition gives it a credible entry point, but the trade is high beta and should be sized small until phase 3 visibility improves.
• Own GS as a low-conviction secondary beneficiary only on any pullback: the real opportunity is not direct exposure but advisory/financing work across the category; expect limited alpha, so keep position sizing modest.
• Avoid chasing GPCR despite optionality: with no direct data edge in this read-through, it remains a long-dated story; any position should be structured as cheap call options only, not common equity.